Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

Abstract

Identification of the correct targets is a key element for successful drug development. However, there are limited approaches for predicting drug targets for specific diseases using omics data, and few have leveraged expression profiles from gene perturbations. We present a novel computational approach for drug target discovery based on machine learning (ML) models. ML models are first trained on drug-induced expression profiles with outcomes defined as whether the drug treats the studied disease. The goal is to “learn” the expression patterns associated with treatment. Then, the fitted ML models were applied to expression profiles from gene perturbations (overexpression (OE)/knockdown (KD)). We prioritized targets based on predicted probabilities from the ML model, which reflects treatment potential. The methodology was applied to predict targets for hypertension, diabetes mellitus (DM), rheumatoid arthritis (RA), and schizophrenia (SCZ). We validated our approach by evaluating whether the identified targets may ‘re-discover’ known drug targets from an external database (OpenTargets). Indeed, we found evidence of significant enrichment across all diseases under study. A further literature search revealed that many candidates were supported by previous studies. For example, we predicted PSMB8 inhibition to be associated with the treatment of RA, which was supported by a study showing that PSMB8 inhibitors (PR-957) ameliorated experimental RA in mice. In conclusion, we propose a new ML approach to integrate the expression profiles from drugs and gene perturbations and validated the framework. Our approach is flexible and may provide an independent source of information when prioritizing drug targets.

Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-of-the-Art Review

“…Many pharmaceutical projects fail due to incorrect target selection [ 168 ], which is an inevitable consequence of hypothesis-driven testing. Zhao and colleagues [ 169 ] addressed this issue by creating ML models that proposed potential treatments by inspecting expression profiles of patients being treated with a drug already proven to be effective and presenting targets that, if targeted, result in similar expression profiles. Their results for finding candidate targets for RA using random forest and gradient boosting machine algorithms showed significant concordance with an external database listing potential.…”

A Stepwise Approach to Analyzing Musculoskeletal Imaging Data With Artificial Intelligence

“…Once data are organized, they can be analyzed to answer research questions about rheumatologic conditions. ML has been used to evaluate expression profiles of patients successfully treated for rheumatoid arthritis (RA) and determine which medication will be effective for patients with a specific expression profile 8 …”

Applications of Deep Learning for Drug Discovery Systems with BigData

“…Therefore, efforts are being made in target gene searches to promote new drug discovery targets based on human or other data [14][15][16]. It is expected that the use of human data such, as omics data and clinical information, can reduce failures due to reliance on animal testing [17,18]. Another benefit is the ability to leverage search results from other disease predictors that share drug discovery targets.…”